Original Article
Economic evaluation of ticagrelor for secondary prevention following acute coronary syndromes
Avaliação económica de ticagrelor em prevenção secundária pós Síndroma Coronário Agudo
a Católica Lisbon School of Business and Economics, Universidade Católica Portuguesa, Lisboa, Portugal
b Unidade de Farmacologia Clínica, Centro Hospitalar de Lisboa Central EPE & Laboratório de Farmacologia Clínica e Terapêutica, Faculdade de Medicina da Universidade de Lisboa, Lisboa, Portugal
c Corporate Affairs & Market Access Department, AstraZeneca - Produtos Farmacêuticos, Lda., Lisboa, Portugal
d Global Clinical Development Department, AstraZeneca, Mölndal, Sweden
Read
9025
Timeswas read the article
2232
Total PDF
6793
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 6 | 8 | 4 | 12 |
| 2025 5 | 56 | 24 | 80 |
| 2025 4 | 33 | 28 | 61 |
| 2025 3 | 54 | 28 | 82 |
| 2025 2 | 47 | 28 | 75 |
| 2025 1 | 50 | 35 | 85 |
| 2024 12 | 30 | 20 | 50 |
| 2024 11 | 45 | 40 | 85 |
| 2024 10 | 41 | 28 | 69 |
| 2024 9 | 45 | 28 | 73 |
| 2024 8 | 49 | 34 | 83 |
| 2024 7 | 33 | 43 | 76 |
| 2024 6 | 38 | 27 | 65 |
| 2024 5 | 41 | 35 | 76 |
| 2024 4 | 42 | 31 | 73 |
| 2024 3 | 42 | 19 | 61 |
| 2024 2 | 34 | 29 | 63 |
| 2024 1 | 24 | 26 | 50 |
| 2023 12 | 20 | 23 | 43 |
| 2023 11 | 27 | 27 | 54 |
| 2023 10 | 19 | 18 | 37 |
| 2023 9 | 21 | 16 | 37 |
| 2023 8 | 38 | 25 | 63 |
| 2023 7 | 18 | 9 | 27 |
| 2023 6 | 26 | 16 | 42 |
| 2023 5 | 34 | 29 | 63 |
| 2023 4 | 23 | 6 | 29 |
| 2023 3 | 35 | 18 | 53 |
| 2023 2 | 32 | 18 | 50 |
| 2023 1 | 29 | 17 | 46 |
| 2022 12 | 28 | 13 | 41 |
| 2022 11 | 34 | 28 | 62 |
| 2022 10 | 29 | 22 | 51 |
| 2022 9 | 25 | 26 | 51 |
| 2022 8 | 37 | 24 | 61 |
| 2022 7 | 30 | 24 | 54 |
| 2022 6 | 31 | 26 | 57 |
| 2022 5 | 31 | 27 | 58 |
| 2022 4 | 31 | 22 | 53 |
| 2022 3 | 24 | 34 | 58 |
| 2022 2 | 44 | 18 | 62 |
| 2022 1 | 59 | 23 | 82 |
| 2021 12 | 26 | 25 | 51 |
| 2021 11 | 127 | 32 | 159 |
| 2021 10 | 111 | 25 | 136 |
| 2021 9 | 45 | 37 | 82 |
| 2021 8 | 32 | 29 | 61 |
| 2021 7 | 35 | 30 | 65 |
| 2021 6 | 26 | 26 | 52 |
| 2021 5 | 34 | 25 | 59 |
| 2021 4 | 42 | 24 | 66 |
| 2021 3 | 54 | 15 | 69 |
| 2021 2 | 63 | 11 | 74 |
| 2021 1 | 28 | 14 | 42 |
| 2020 12 | 43 | 8 | 51 |
| 2020 11 | 24 | 11 | 35 |
| 2020 10 | 34 | 10 | 44 |
| 2020 9 | 64 | 4 | 68 |
| 2020 8 | 34 | 7 | 41 |
| 2020 7 | 59 | 10 | 69 |
| 2020 6 | 46 | 5 | 51 |
| 2020 5 | 41 | 12 | 53 |
| 2020 4 | 52 | 21 | 73 |
| 2020 3 | 50 | 10 | 60 |
| 2020 2 | 84 | 22 | 106 |
| 2020 1 | 38 | 14 | 52 |
| 2019 12 | 76 | 9 | 85 |
| 2019 11 | 30 | 12 | 42 |
| 2019 10 | 42 | 9 | 51 |
| 2019 9 | 57 | 7 | 64 |
| 2019 8 | 37 | 4 | 41 |
| 2019 7 | 44 | 14 | 58 |
| 2019 6 | 30 | 7 | 37 |
| 2019 5 | 37 | 15 | 52 |
| 2019 4 | 34 | 14 | 48 |
| 2019 3 | 59 | 9 | 68 |
| 2019 2 | 58 | 15 | 73 |
| 2019 1 | 61 | 8 | 69 |
| 2018 12 | 58 | 20 | 78 |
| 2018 11 | 258 | 23 | 281 |
| 2018 10 | 631 | 29 | 660 |
| 2018 9 | 157 | 14 | 171 |
| 2018 8 | 137 | 9 | 146 |
| 2018 7 | 67 | 6 | 73 |
| 2018 6 | 78 | 9 | 87 |
| 2018 5 | 59 | 13 | 72 |
| 2018 4 | 79 | 7 | 86 |
| 2018 3 | 111 | 4 | 115 |
| 2018 2 | 38 | 2 | 40 |
| 2018 1 | 32 | 5 | 37 |
| 2017 12 | 78 | 6 | 84 |
| 2017 11 | 40 | 6 | 46 |
| 2017 10 | 56 | 8 | 64 |
| 2017 9 | 37 | 5 | 42 |
| 2017 8 | 48 | 8 | 56 |
| 2017 7 | 51 | 13 | 64 |
| 2017 6 | 56 | 9 | 65 |
| 2017 5 | 53 | 8 | 61 |
| 2017 4 | 66 | 23 | 89 |
| 2017 3 | 68 | 29 | 97 |
| 2017 2 | 110 | 2 | 112 |
| 2017 1 | 56 | 2 | 58 |
| 2016 12 | 69 | 7 | 76 |
| 2016 11 | 44 | 3 | 47 |
| 2016 10 | 39 | 2 | 41 |
| 2016 9 | 28 | 7 | 35 |
| 2016 8 | 12 | 2 | 14 |
| 2016 7 | 15 | 3 | 18 |
| 2016 6 | 14 | 3 | 17 |
| 2016 5 | 12 | 2 | 14 |
| 2016 4 | 36 | 17 | 53 |
| 2016 3 | 65 | 31 | 96 |
| 2016 2 | 78 | 34 | 112 |
| 2016 1 | 92 | 34 | 126 |
| 2015 12 | 70 | 32 | 102 |
| 2015 11 | 78 | 22 | 100 |
| 2015 10 | 63 | 29 | 92 |
| 2015 9 | 55 | 23 | 78 |
| 2015 8 | 68 | 22 | 90 |
| 2015 7 | 45 | 13 | 58 |
| 2015 6 | 66 | 17 | 83 |
| 2015 5 | 47 | 11 | 58 |
| 2015 4 | 47 | 30 | 77 |
| 2015 3 | 39 | 18 | 57 |
| 2015 2 | 93 | 44 | 137 |
Show all
